Live Breaking News & Updates on Baseline Over

Stay updated with breaking news from Baseline over. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023 ....

Lisah Lancaster , Toby Maher , Christopher Keenan , Los Angeles , Drug Administration , Bexotegrast Clinical Development Next , University Of Southern California , Corporate Communications , Vanderbilt University Medical Center , Pliant Therapeutics Inc , European Medicines Agency , Group Demonstrated Treatment Effects Including Durable Improvements , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition ,

Pliant Therapeutics Announces Positive Long-Term Data from

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care. ....

Lisah Lancaster , Toby Maher , Los Angeles , Christopher Keenan , Group Demonstrated Treatment Effects Including Durable Improvements , Corporate Communications , Drug Administration , Vanderbilt University Medical Center , European Medicines Agency , Bexotegrast Clinical Development Next , Pliant Therapeutics Inc , University Of Southern California , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition ,

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023 ....

Lisah Lancaster , Christopher Keenan , Los Angeles , Toby Maher , Drug Administration , Bexotegrast Clinical Development Next , Corporate Communications , Group Demonstrated Treatment Effects Including Durable Improvements , Keck School Of Medicine , Vanderbilt University Medical Center , University Of Southern California , Globenewswire Inc , Pliant Therapeutics Inc , European Medicines Agency , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act ,